1.
J Med Chem
; 48(16): 5092-5, 2005 Aug 11.
Article
in English
| MEDLINE
| ID: mdl-16078826
ABSTRACT
Tanaproget represents a potential first-in-class nonsteroidal PR agonist for contraception with improved safety and side effect profiles versus currently available steroidal oral contraceptives. Additional SAR, biological activity, and structural information from a tanaproget/hPR-LBD (hPR-LBD = human progesterone receptor ligand binding domain) cocrystal structure will also be presented.